Royalty Pharma plc Stock Analysis & AI Score
Royalty Pharma plc (RPRX) has an ST Score of 43.6 (C), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $62.67 price target (+7.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Royalty Pharma plc (RPRX) has an ST Score of 43.6 (C), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $62.67 price target (+7.5% upside).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationF
All factor grades
- ProfitabilityA+
- MomentumA-
- ForecastC+
- Financial StrengthD-
- GrowthD-
- ValuationF
- Piotroski6/9
Contact
RPRX stock: frequently asked questions
What is RPRX's ST Score?
Royalty Pharma plc (RPRX) has an ST Score of 43.6 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RPRX a buy, hold, or sell?
Analysts rate RPRX a Buy, with a price target of $62.67 (+7.5% vs the current price). Our ST Score grades it C (43.6/100). The ST Score is a data-driven signal, not a recommendation.
What are RPRX's factor grades?
Valuation F, Profitability A+, Financial Strength D-, Momentum A-, Growth D-, Forecast C+.
What is RPRX's valuation grade?
Royalty Pharma plc (RPRX) earns a valuation grade of F, measured against Medical - Pharmaceuticals peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RPRX's growth grade?
Royalty Pharma plc (RPRX) earns a growth grade of D-, measured against Medical - Pharmaceuticals peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RPRX's profitability grade?
Royalty Pharma plc (RPRX) earns a profitability grade of A+, measured against Medical - Pharmaceuticals peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RPRX's financial strength grade?
Royalty Pharma plc (RPRX) earns a financial strength grade of D-, measured against Medical - Pharmaceuticals peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for RPRX?
The average analyst price target for Royalty Pharma plc (RPRX) is $62.67 from 11 analysts, which is +7.5% versus the recent price of $58.29.
What is RPRX's Piotroski score?
Royalty Pharma plc (RPRX) has a Piotroski F-Score of 6 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.